IMVT Immunovant

Immunovant to Host Graves’ Disease Program Update on September 9, 2024

Immunovant to Host Graves’ Disease Program Update on September 9, 2024

Investor webcast on Monday, September 9th at 8:00 a.m. ET

NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Monday, September 9th at 8:00 a.m. ET to provide an update on its Graves’ Disease (GD) program.

The update will consist of new epidemiologic data characterizing the potentially addressable market, additional results from the Phase 2 study of batoclimab, and an overview of the IMVT-1402 development program in GD.

Webcast Details

The company will host a webcast at 8:00 a.m. ET on Monday, September 9th. Please click to register for the event. The live webcast will also be available under the section of Immunovant’s website. A replay of the event and presentation will be available immediately following the event.

About Immunovant, Inc.

Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit .

Investor Contact:

Renee Barnett, MBA

Chief Financial Officer

Immunovant, Inc.

Source: Immunovant Inc.



EN
05/09/2024

Underlying

IMVTImmunovant

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Immunovant

 PRESS RELEASE
Free
IMVT IMMUNOVANT

Immunovant Provides Development Updates and Reports Financial Results ...

Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024 Five Investigational New Drug (IND) applications cleared across a range of therapeutic areas and FDA divisions for lead asset, IMVT-1402Proof of concept data from batoclimab trial in Graves’ disease (GD) demonstrate potential of deeper IgG reduction with potent FcRn inhibition to transform treatment for GD patients who are not well controlled on antithyroid drugs (ATDs); initiation of potentially registrational trial to evaluate IMVT-1402 in GD expected by year endIND cleared for I...

16h / 26m 1 EN
 PRESS RELEASE
Free
IMVT IMMUNOVANT

Immunovant Announces Oral Presentation of Late Breaking Abstract for P...

Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves’ Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that data from the Phase 2a trial of batoclimab in Graves’ disease will be the subject of an oral presentation of a late-breaking abstract accepted for the 2024 American Thyroid Association (ATA) Annual Meeting being held Oct...

October 29, 2024 1 EN
 PRESS RELEASE
Free
IMVT IMMUNOVANT

Immunovant Provides Update on Graves’ Disease Development Program

Immunovant Provides Update on Graves’ Disease Development Program High dose batoclimab achieved 76% response rate in patients uncontrolled on antithyroid drugs (ATDs) at week 12High dose batoclimab achieved 56% ATD-Free response rate in patients uncontrolled on ATDs at week 12Strong correlation observed between degree of IgG lowering and clinical outcomes yields potential best-in-class and first-in-class opportunity for IMVT-1402 in Graves’ Disease (GD)Real world claims data indicates 25-30% of Graves’ Disease patients per year are uncontrolled on ATDs with minimal to no existing therapeuti...

September 9, 2024 1 EN
 PRESS RELEASE
Free
IMVT IMMUNOVANT

Immunovant to Host Graves’ Disease Program Update on September 9, 2024

Immunovant to Host Graves’ Disease Program Update on September 9, 2024 Investor webcast on Monday, September 9th at 8:00 a.m. ET NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Monday, September 9th at 8:00 a.m. ET to provide an update on its Graves’ Disease (GD) program. The update will consist of new epidemiologic data characterizing the potentially addressable market, additional results from...

September 5, 2024 1 EN
 PRESS RELEASE
Free
IMVT IMMUNOVANT

Immunovant Reports Financial Results and Provides Corporate Updates fo...

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2024 Completed enrollment in batoclimab pivotal Myasthenia Gravis (MG) trial; top-line results and initiation of a potentially registrational program for IMVT-1402 on track for fiscal year end (March 31, 2025) Progressed development of lead asset IMVT-1402 with 3 Investigational New Drug (IND) applications expected to be active by calendar year end (December 31, 2024)Progressed Graves’ disease (GD) program and on track to disclose additional results from the batoclimab study in GD as well as ...

August 6, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch